Kaye Edward M. MD

SEC source: 0001522780-26-000007 · form4-08192026_120851.xml · nonDerivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,557

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.

SEC source: 0001522780-26-000007 · form4-08192026_120851.xml · nonDerivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,194

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

SEC source: 0001522780-26-000007 · form4-08192026_120851.xml · derivative · entry 4

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,250 shares

Expires 2026-08-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each performance stock unit represents a right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001522780-26-000007 · form4-08192026_120851.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,124

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-26-000081 · form4.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,434

F1 · kind: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

SEC source: 0001522780-26-000004 · form4-06052026_080652.xml · derivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,786

Underlying: Common Stock · 17,786 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

SEC source: 0001061983-26-000066 · form4.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,283

SEC source: 0001061983-26-000058 · form4.xml · derivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,301

Underlying: Common Stock · 4,301 shares

Expires 2036-05-26

SEC source: 0001061983-26-000058 · form4.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,216

SEC source: 0001061983-26-000040 · form4.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,365

F1 · kind: Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested.

SEC source: 0001522780-26-000002 · form4-03172026_090329.xml · derivative · entry 4

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,500

Underlying: Common Stock · 26,250 shares

Expires 2028-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

F3 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the Issuer through each vesting date.

SEC source: 0001522780-26-000002 · form4-03172026_090329.xml · derivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,500

Underlying: Common Stock · 35,500 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.

F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date.

SEC source: 0001522780-26-000002 · form4-03172026_090329.xml · nonDerivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,874

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001522780-26-000002 · form4-03172026_090329.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,624

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-082136 · ownership.xml · derivative · entry 8

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,534 shares

Expires 2029-08-27

F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

SEC source: 0001193125-26-082136 · ownership.xml · derivative · entry 7

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,323 shares

Expires 2030-05-14

F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

SEC source: 0001193125-26-082136 · ownership.xml · derivative · entry 6

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2031-06-15

F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

SEC source: 0001193125-26-082136 · ownership.xml · derivative · entry 5

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,000 shares

Expires 2032-06-14

F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

SEC source: 0001193125-26-082136 · ownership.xml · derivative · entry 4

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,000 shares

Expires 2033-06-14

F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

SEC source: 0001193125-26-082136 · ownership.xml · derivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,489 shares

Expires 2034-06-12

F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

SEC source: 0001193125-26-082136 · ownership.xml · derivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,034 shares

Expires 2035-06-09

F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

SEC source: 0001193125-26-082136 · ownership.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.

F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.

SEC source: 0001061983-26-000006 · form4.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,174

F1 · kind: Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of our Board of Directors.

SEC source: 0001522780-25-000010 · form4-12102025_091241.xml · nonDerivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,124

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.25 per share, inclusive.

SEC source: 0001522780-25-000010 · form4-12102025_091241.xml · nonDerivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,455

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.95 per share, inclusive.

SEC source: 0001522780-25-000010 · form4-12102025_091241.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,729

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.90 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 2 and 3 of this Form 4.

SEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 6

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,554

F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $31.96 per share, inclusive.

SEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 5

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,054

F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.69 to $31.61 per share, inclusive.

SEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 4

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,735

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.

SEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,102

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.

SEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,333

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4.

SEC source: 0001522780-25-000008 · form4-12042025_011205.xml · nonDerivative · entry 5

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,305

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive.

SEC source: 0001522780-25-000008 · form4-12042025_011205.xml · nonDerivative · entry 4

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,956

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive.

SEC source: 0001522780-25-000009 · form4-12062025_011216.xml · derivative · entry 7

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,250 shares

Expires 2025-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F9 · derivative.exercise_date: Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

SEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,555

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001522780-25-000008 · form4-12042025_011205.xml · nonDerivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,375

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive.

SEC source: 0001522780-25-000008 · form4-12042025_011205.xml · nonDerivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,780

F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5.

SEC source: 0001061983-25-000040 · form4.xml · derivative · entry 5

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2027-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018.

SEC source: 0001061983-25-000040 · form4.xml · derivative · entry 4

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,064 shares

Expires 2027-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option shall vest and become exercisable as to 8,064 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018.

SEC source: 0001061983-25-000040 · form4.xml · nonDerivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,977

SEC source: 0001061983-25-000040 · form4.xml · nonDerivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,041

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-25-000040 · form4.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,041

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001522780-25-000008 · form4-12042025_011205.xml · derivative · entry 6

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,317 shares

Expires 2025-12-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F7 · derivative.exercise_date: 21,591 restricted stock units vested on December 1, 2024 and 4,317 vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date.

SEC source: 0001061983-25-000031 · form4.xml · derivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,175 shares

Expires 2026-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option shall vest and become exercisable as to 5,175 shares divided into equal monthly installments such that the option shall be 100% vested on January 1, 2017.

SEC source: 0001061983-25-000031 · form4.xml · nonDerivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,977

SEC source: 0001061983-25-000031 · form4.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,152

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001061983-25-000011 · form4.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,977

F1 · kind: Director equity in lieu of cash retainer program.

SEC source: 0001522780-25-000007 · form4-10102025_081021.xml · derivative · entry 3

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 542,801

Underlying: Common Stock · 25,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

F2 · derivative.exercise_date: The option vested as to 1/4th of the total award on October 17, 2018, with another 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Accordingly, this stock option is now fully vested.

SEC source: 0001522780-25-000007 · form4-10102025_081021.xml · nonDerivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,124

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.

SEC source: 0001522780-25-000007 · form4-10102025_081021.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,124

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.